CDK4/6 inhibition in breast cancer: current practice and future directions

Cited by papers we hold 6

• Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer · 2023
  No notice
• CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal · 2022
  No notice
• Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer · 2021
  No notice
• Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer · 2021
  No notice
• Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma · 2020
  No notice
• Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.